|Conditional recommendation based on very-low-quality evidence; may consider adding MTX when patients have demonstrated partial response to the current TNFi biologic therapy, especially if the TNFi biologic is a monoclonal antibody.| |
|6. Switch to an IL-17i biologic over switching to an IL-12/23i biologic (PICO 29)|Low (90â€“93, 95, 99, 100)|